In vitro activity of the echinocandins. How it can be evaluated?;Actividad in vitro de las equinocandinas ¿Cómo debe evaluarse?

Revista Iberoamericana de Micologia

Volumn 22, Issue 3, 2005, Pages 133-140

  Pastor, F Javier ^a   Guarro, Josep ^a  

^a FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

Author keywords

Echinocandins; Endpoints; Pharmacodynamics

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; BIFONAZOLE; CASPOFUNGIN; ECHINOCANDIN; FLUCYTOSINE; POSACONAZOLE; RAVUCONAZOLE; TEBUCONAZOLE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ASPERGILLUS; CANDIDA; CLINICAL TRIAL; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DILUTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG SENSITIVITY; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; META ANALYSIS; MICRODILUTION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; RELIABILITY; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW;

ASPERGILLUS; CANDIDA;

EID: 28444451092     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1130-1406(05)70026-7     Document Type: Review

References (102)

1. Anaissie E. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review. Clin Infect Dis 1992; 14(Suppl.): S43-S53.
2. Andes D. In vitro pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 2003; 47: 1179-1186.
3. Andes D. Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance. Drug Resist Updat 2004; 7: 185-194.
4. Andes D, Marchillo K, Lowther J, Bryskier A, Stamstad T, Conklin R. In vivo pharmacodynamics of HMK 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 1187-1192.
5. Anon JB, Jacobs MR, Poole MD, Ambrose PG, Benninger MS, Hadley JA, Craig WA; Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 130 (Suppl. 1): 1-45.
6. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001 ; 45: 327-330.
7. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphptericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-247.
8. Arikan S, Yurdakul P, Hascelik G. Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. Antimicrob Agents Chemother 2003; 47: 2640-2643.
9. Bartizal K, Gill CJ, Abruzzo GK, Flattery AM, Kong L, Scott PM, Smith JG, Leighton CE, Bouffard A, Dropinski JF, Balkovec J. In vitro preclinical evaluation studies with the echinocandin antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2326-2332.
10. Bennet JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradshaw M, Haywood H, McGee ZA, Cate TR, Cobbs CG, Warner JF, Alling DW. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 19: 126-131.
11. Bowman JC, Scott Hicks P, Kurtz MB, Rosen H, Schmatz DM, Liberator PA, Douglas CM. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46: 3001-3012.
12. Chiou CC, Mavrogiorgos N, Tillem E, Hector R, Walsh TJ. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother 2001; 45: 3310-3321.
13. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12.
14. Dannaoui E, Lorthoraly G, Dromer F. Techniques d'étude des associations d'antifongiques in vitro and in vivo chez l'animal. J Mycol Med 2003; 13: 73-85.
15. Dannaoui E, Lorthoraly G, Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother 2004; 48: 970-978.
16. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Ann Rev Microbiol 1994; 48: 471-497.
17. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-615.
18. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-1151.
19. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40: 401-414.
20. Dowell SF, Butler JC, Geibink GS. Acute otitis media: management and surveillance in an era of pnemococcal resistance - a report from the Drug-Resistant Streptococcus pneumoniae Working Group. Pediatr Infect Dis J 1999; 18: 1-9.
21. Eagle H, Musselman AD. The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 1948; 88: 99-131.
22. Eliopoulos GM, Moellering RC. Antimicrobial combinations. En: V. Lorian (Ed.) Antibiotics in laboratory medicine. Baltimore, Williams & Wilkins 1991 : 432-492.
23. Ernst EJ, Klepser ME, Ernst ME, Messer SA, Pfaller MA. In vitro pharmacodynamics properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis 1999; 33: 75-80.
24. Ernst E, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents. Antimicrob Agents Chemother 2000; 44: 1108-1111.
25. Ernst ME, Klepser ME, Wolfe EJ, Pfaller MA. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida spp. Diagn Microbiol Infect Dis 1996; 26: 125-131.
26. Ernst EJ, Roling EE, Petzold CR, Keele DJ, Klepser ME. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 2002; 46: 3846-3853.
27. Espinel-Ingroff A. Clinical relevance of antifungal resistance. Infect Dis Clin N Am 1997; 11: 929-944.
28. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeast. J Clin Microbiol 1998; 36: 2950-2956.
29. Espinel-Ingroff. Clinical utility of in vitro antifungal susceptibility testing. Rev Esp Quimioterap 2000; 13: 161-166.
30. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-136.
31. Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). Antimicrob Agents Chemother 2003; 41 : 403-409.
32. Espinel-Ingroff A, Bartlett M, Chaturvedi V, Ghannoum M, Hazen KC, Pfaller MA, Rinaldi M, Walsh TJ. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. Antimicrob Agents Chemother 2001 ; 45: 1828-1835.
33. Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG. Optimal testing conditions for determining MICs and minimal fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol 2002; 40: 3776-3781.
34. Espinel-Ingroff A, Pfaller M, Messer SA, Knapp CC, Holliday N, Killian SB. Multicenter comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J Clin Microbiol 2004; 42: 718-721.
35. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1747-1751.
36. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microb Rev 1999; 12: 501-517.
37. González GM, Tijerina R, Najvar LK, Bocanegra R, Luther M, Rinaldi MG, Graybill JR. Correlation between antifungal susceptibilities of Coccidioides immitis and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 2001 ; 45: 1854-1859.
38. Gonzalez C, Venzon D, Lee S, Mueller BM, Pizzo PA, Walsh TJ. Risk factors for fungemia in children infected with human immunodeficiency virus: a case-control study. Clin Infect Dis 1996; 23: 515-521.
39. Green LJ, Marder P, Mann LL, Chio LC, Current WL. LY303366 exhibits rapid and potent fungicidal activity in flowcytometric assays of yeasts viability. Antimicrob Agents Chemother 1999; 43: 830-835.
40. Groll AH, Kolve H. Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Microbiol Infect Dis 2004; 23: 256-270.
41. Groll AH, Mickiene D, Petraitis V, Petraitiene R, Ibrahim KH, Pisticelli SC, Bekersky I, Walsh TJ. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001; 45: 3322-3327.
42. Groll AH, Mickiene D, Petraitiene R, Petraitis V, Lyman CA, Bacher JS, Pisticelli SC, Walsh TJ. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001; 45: 2845-2855.
43. Guarro J, Gené J. Opportunistic fusarial infections in humans. Eur J Clin Microbiol Infect Dis 1995; 14: 741-754.
44. Gunderson SM, Hoffman H, Ernst EJ, Pfaller MA, Klepser ME. In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect. Antimicrob Agents Chemother 2000; 44: 2887-2890.
45. Hadfield TL, Smith MB, Winn RE, Rinaldi MG, Guerra C. Mycoses caused by Candida lusitaniae. Rev Infect Dis 1987; 9: 1006-1012.
46. Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 1995; 9: 1045-1074.
47. Hall GS, Myles C, Pratt KJ, Washington JA. Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis. Antimicrob Agents Chemother 1988; 32: 1331-1335.
48. Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993; 6: 1-21.
49. Imhof A, Balajee SA, Marr KA. New methods to asses susceptibilities of Aspergillus isolates to caspofungin. J Clin Microbiol 2003; 41: 5683-5688.
50. Kang Z, Huang L, Krieg U, Mauler-Machnik A, Buchenauer H. Effects of tebuconazole on morphology, estructure, cell wall components and trichothecene production of Fusarium culmorum in vitro. Pest Manag Sci 2001; 57: 491-500.
51. Klepser ME, Ernst EJ, Ernst ME, Messer SA, Pfaller MA. Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Antimicrob Agents Chemother 1998; 42: 1387-1391.
52. Klepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob Agents Chemother 1998; 42: 1207-1212.
53. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother 1997; 41: 1392-1395.
54. Klepser ME, Wolfe EJ, Pfaller MA. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. J Antimicrob Chemother 1998; 41: 397-401.
55. Kontoyiannis DP, Lewis RE. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist Update 2003; 6: 257-269.
56. Kurtz MB, Heat IB, Marrinan J, Dreikorn S, Onishi J, Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480-1489.
57. Lewis RE, Klepser ME, Pfaller MA. In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods. Diagn Microbiol Infect Dis 2000; 36: 101-105.
58. Lin S, Schrariz J, Teutsch S. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-366.
59. Manavathu EK, Alangaden GJ, Chandrasekar PH. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother 2003; 51: 1423-1425.
60. Mikamo H, Sato Y, Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 2000; 46: 485-487.
61. Moore CB, Sayers N, Mosquera J, Slayen J, Denning DW. Antifungal drug resistance in Aspergillus. J Infect 2000; 41: 203-220.
62. Mouton JW, van Ogtrop ML, Andes D, Craig WA. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother 1999; 43: 2473-2478.
63. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005; 18: 163-194.
64. Nakai T, Uno J, Ikeda F, Tawara S, Nishimura K, Miyaji M. In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like ans mycelial forms. Antimicrob Agents Chemother 2003; 47: 1376-1381.
65. National Committee for Clinical Laboratory Standars. Reference method for broth dilution susceptibility testing of yeast. Approved standard M27-A. National Committee for Clinical Laboratory Standars. Wayne, USA, 1997.
66. nd ed. Document M23-A2. National Comité for clinical laboratory standards, Wayne, PA 2000.
67. National Committee for Clinical Laboratory Standars. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M7-A5. National Committee for Clinical Laboratory Standars. Wayne, USA, 2000.
68. National Committee for Clinical Laboratory Standars. Performance Standards for antimicrobial disk susceptibility test. Approved standard M7-A7. National Committee for Clinical Laboratory Standars. Wayne, USA, 2000.
69. National Committee for Clinical Laboratory Standars. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standars. Wayne, USA, 2002.
70. Nguyen MH, Clancy CJ, Yu VL, Yu YV, Morris AJ, Snydman DR, Sutton DA, Rinaldi MG. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998; 177: 425-430.
71. Niwa T, Yokota Y, Tokunaga A, Yamato Y, Kagayama A, Fujiwara T, Hatakeyama J, Anezaki M, Ohtsuka Y, Takagi A. Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol Pharm Bull 2004; 27: 1154-1156.
72. Oaklley KL, Moore CB, Denning DW. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother 1998; 42: 2726-2730.
73. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
74. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowtiz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United states. Antimicrob Agents Chemother 2003; 47: 3149-3154.
75. Osumi M, Yamada N, Yamada Y, Yamaguchi H. The effect of bifonazole on the structure of Trichophyton mentagrophytes. Dermatologica 1984; 169 (Suppl.1): 19-31.
76. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189.
77. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002; 46: 3039-3041.
78. Petraitiene R, Petraitis V, Groll AH, Candelario M, Sein T, Bell A, Lyman CA, McMillian CL, Bacher J, Walsh TJ. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother 1999; 43: 2148-2155.
79. Petraitis V, Petraitiene R, Groll AH, Roussillon K, Hemmings M, Lyman CA, Sein T, Bacher J, Bekersky I, Walsh TJ. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46: 1857-1869.
80. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs and modes of transmission. Clin Infect Dis 1996; 22 (Suppl. 2): S89-S94.
81. Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 2003; 47: 1068-1071.
82. Pfaller MA, Messer SA, Houston A, Mills K, Bolmstrom A, Jones RN. Evaluation of Etest method for determining caspofungin susceptibilities of 726 clinical isolates of Candida species. J Clin Microbiol 2001; 39: 4387-4389.
83. Pontón J, Rüchel R, Clemons KV, Colemans DC, Grillot R, Guarro J, Aldebert D, Ambroise-Thomas P, Cano J, Carrillo-Muñoz AJ, Gené J, Pinel C, Stevens DA, Sullivan DJ. Emerging pathogens. Med Mycol 2000; 38 (Suppl.1): 225-236.
84. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC, Rinaldi MG, Sheehan DJ, Warnock DW. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microb Rev 2001; 14: 643-658.
85. Rodero L, Cordoba S, Cahn P, Soria M, Lucarini M, Davel G, Kaufman S, Canteros C, Guelfand L. Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS. Med Mycol 2000; 38: 201-207.
86. Serena C, Fernández-Torres B, Pastor FJ, Trilles L, Lazéra MS, Nolard N, Guarro J. In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus. Antimicrob Agents Chemother (In press).
87. Serena C, Ortoneda M, Capilla J, Pastor FJ, Sutton DA, Rinaldi MG, Guarro J. In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization. Antimicrob Agents Chemother 2003; 47: 3161-3164.
88. Serena C, Pastor FJ, Gilgado F, Mayayo E, Guarro J. Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis. Antimicrob Agents Chemother 2005; 49: 497-502.
89. Serrano MC, Valverde-Conde A, Chavez MM, Bernal S, Claro RM, Peman J, Ramírez M, Martín-Mazuelos E. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis 2003; 45: 131-135.
90. Shalit I, Shadkchan Y, Samra Z, Osherov N. In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points. Antimicrob Agents Chemother 2003; 47: 1416-1418.
91. Spitzer ED, Travis SJ, Kobayashi GS. Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 1988; 7: 80-81.
92. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004; 48: 3407-3411.
93. Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchel GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46: 739-745.
94. Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, Goto T, Tomishima M, Ohki H, Yamada A, Kawabata K, Takasugi H, Sakane K, Tanaka H, Matsumoto F, Kuwahara S. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44: 57-62.
95. Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 2004; 23: 805-812.
96. Turnidge JD, Ferraro MJ, Jorgensen JH. Susceptibility test methods: general considerations. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH (Eds.) Manual of Clinical Microbiology. Washington DC, ASM Press, 2003; 1102-1107.
97. Verweij PE, Oakley KL, Morrissey J, Morrissey G, Denning DW. Efficacy of LY303,366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother 1998; 42: 873-878.
98. Vitale RG, Mouton JW, Afeltra J, Meis JF, Verweij PE. Method for measuring postantifungal effect in Aspergillus species. Antimicrob Agents Chemother 2002; 46: 1960-1965.
99. Walter EA, Bowden RA. Infection in the bone marrow transplant recipient. Infect Dis Clin North Am 1995; 9: 823-847.
100. Watabe E, Nakai T, Matsumoto S, Ikeda F, Hatano K. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob Agents Chemother 2003; 47: 1995-1998.
101. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464-1471.
102. Wingard JR, Elfenbein GJ. Host immunologic augmentation for the control of infection. Infect Dis Clin N Am 1996; 10: 345-364.